The $495 Million NEC Victory & The Bard PowerPort Setback

Inside the Underground Network of Child Abuse (And Why Nobody's Stopping It)

Key Takeaways * Lee Floyd spent over a decade defending major corporations like Johnson & Johnson and Bayer before transitioning to plaintiff's work in 2020. * A detailed conversation about systemic abuse at Cumberland Hospital prompted her to leave her corporate defense partnership within a single week to represent injured children. * Floyd secured a $360 million verdict in her very first trial on the plaintiff side, establishing the largest verdict in Virginia history. * Institutional abuse cases involve severe emotional challenges, with clients frequently experiencing intense trauma responses during written discovery and depositions. * Legal teams handling high-trauma cases require active internal support structures, including mandatory therapy schedules and flexible time-off policies, to protect staff members from vicarious trauma. * Effective intake protocols for sensitive litigation allow both the potential client and the staff member to pause or reschedule discussions if the content becomes too overwhelming.

Mass Tort Power Rankings: The "Rocket Docket" Surges & A Game-Changing $27M Precedent

Key Takeaways * The #1 Ranked Mass Tort remains the undisputed heavyweight champion of the board after securing a staggering $27 million settlement on a school district bellwether case that was originally selected entirely by the defense. * Depo Provera has officially broken into the top three as a historic "rocket docket" under Judge Rogers, on track to advance from MDL inception to a December trial date in under two years. * Hair Relaxer securely holds the #2 spot on the rankings with a steady influx of filings pushing the docket toward 12,000 cases as Daubert decisions loom this fall. * Tech litigation bottlenecks are prompting defense firms to pivot, with corporate targets in the Roblox litigation aggressively trying to force 160 MDL cases into individual state-by-state minor arbitration. * Weight Loss Drug dockets require a dual-screening approach from intake teams, as litigation expands concurrently across separate gastrointestinal injury and vision loss MDLs.

The Private Equity Shift: Turning Your Law Firm From a Founder-Led Practice to a Scalable Asset

Key Takeaways * Personal injury firms attract private capital because their high-volume, mass-advertising models offer predictable cash flow, unlike mass torts dockets that have undefined timelines and cash flow volatility. * Management Services Organizations (MSOs) allow outside investors to buy into the legal space by owning the service-providing business rather than the regulated law firm equity itself. * Alternative Business Structures (ABS) in jurisdictions like Arizona and Puerto Rico permit non-lawyers to own direct equity in law firms, providing a different pathway for institutional funding. * A law firm's valuation depends heavily on separating the business operations from the founder. Firms built entirely around a single attorney's face and reputation carry high transition risk and receive lower valuations. * Institutional capital and artificial intelligence are driving a massive spending war in case acquisition. Independent trial attorneys may eventually need to join large capitalized firms to access major cases. * Post-acquisition failures often stem from regulatory overreach or a breakdown in trust between the investing partners and the practicing attorneys.

Inside the $70B Opioid Litigation and the New Battle Against Pharmacy Benefit Managers

Key Takeaways * Paul Farrell Jr. led the legal strategy that recovered approximately $70 billion in national opioid settlements by filing lawsuits against every level of the pharmaceutical supply chain. * The settlement funds are legally structured within all 50 states to guarantee they are spent strictly on addiction treatment and abatement rather than disappearing into general government budgets. * The litigation began by utilizing an overlooked West Virginia code section that grants county commissioners explicit legal standing to sue corporations for creating a public nuisance. * While the cases against manufacturers, distributors, and pharmacies are nearly finished, the legal focus has shifted to holding Pharmacy Benefit Managers accountable for controlling drug formularies and using vertical integration to drive the epidemic. * The legal team proved corporate misconduct by demonstrating "diversion," where massive quantities of pills were sent to small towns with no objective medical justification. * Farrell extended his antitrust litigation strategy to take on Google, representing independent newspaper publishers whose advertising revenue was destroyed by digital advertising monopolies and walled garden ecosystems. * Artificial intelligence poses a new challenge for content creators by scraping publisher text and displaying answers directly, which threatens to eliminate the financial incentive to create original news.

The Battle for Accountability: Zuckerberg’s Testimonial Pressure, Rocket Dockets, and Emerging Mass Torts

Key Takeaways * Social Media Litigation Shifts to School Districts: The first bellwether school district trial is set for next month against Meta in a rural Kentucky district, following massive pre-trial settlements by YouTube, Snapchat, and TikTok. * Depo-Provera Moving at Record Speed: With expert depositions complete and Daubert motions fully underway, the litigation is on a strict "rocket docket" pacing toward a crucial June 24, 2026 hearing and a December trial. * GLP-1 Vision Loss Risk Intensifies: A new study published in JAMA Network Open demonstrates that GLP-1 weight loss drug users face a nearly three times higher risk of developing NAION (vision loss). * Projected Growth for Weight Loss Dockets: While the vision loss litigation currently holds only a few hundred cases, experts project it could scale 10x up to 3,000 to 5,000 total cases as scientific data continues to mount. * May JPML Brings High-Stakes New Torts: The May 28, 2026 JPML hearing will evaluate consolidating Dupixent (deemed an 80-90% slam dunk) and Spinal Cord Stimulators against Abbott and Boston Scientific (facing complex multi-defendant hurdles).